Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.

Year-to-date money raised in public, private and other financings of biopharma companies.

These graphs compare the performance of the biotech stocks for all of 2025 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

Biopharma money raised to-date and by month in 2023, including public, private and other financings.

A preview of the next edition of BioWorld, June 6, 2025

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akeso, Avadel, Formycon, Hutchmed, Innovent, Sydnexis, Telix, Tempest, Vigeneron.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alvotech, Basilea, Casma, Cullinan, Dr. Reddy’s, Genrix, Harmony, Immunoprecise, Lupin, Neurop, Ocugen, Pincell, Pfizer, Scinai, Seyltx.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Corcept, Duality, Immunic, Maia, Novartis, Regenxbio.

Biopharmas raising money in public or private financings, including: Alvotech, Cellectar, Qure.